Le Lézard
Classified in: Health
Subjects: MAV, CFG

Media Advisory - Deputy Prime Minister's itinerary for Saturday, March 30, 2024


Note: All times local.

TORONTO, March 29, 2024 /CNW/ -

1:00 p.m.

The Deputy Prime Minister will make a health care announcement in advance of the 2024 federal budget. The Minister of Mental Health and Addictions and Associate Minister of Health, Ya'ara Saks, will also be in attendance. A media availability will follow.




Notes for media:



?  Media wishing to cover the event are asked to arrive no later than 12:30 p.m.



?  Media must register by contacting [email protected].

This document is also available at https://deputypm.canada.ca/en

SOURCE Deputy Prime Minister's Office


These press releases may also interest you

at 16:30
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024
BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on Thursday, May 16, 2024 after market hours. A presentation on the Company's first quarter 2024 results by...

at 16:25
IQVIA CFO Ron Bruehlman to Speak at the Bank of America Health Care Conference on May 14, 2024
IQVIA Holdings Inc. ("IQVIA") announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local...

at 16:25
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter...

at 16:25
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. , today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update. Financial Highlights In connection with the exit of the Fintech Platform business, the results of the...

at 16:20
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Kite, a Gilead Company , and Arcellx, Inc. today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma...

at 16:20
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Arcellx, Inc. and Kite, a Gilead Company , today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma...

More news about Health...


News published on and distributed by: